The US Food and Drug Administration's Pharmacy Compounding Advisory Committee is meeting on 23-24 July 2026 to consider whether specialised compounding pharmacies should be allowed to make popular wellness peptides that were restricted under regulations introduced during the Biden administration. The decision matters because demand for these substances has continued despite the restrictions, reportedly pushing consumers towards unregulated overseas suppliers, while health officials and scientists remain divided over whether the peptides are safe enough to permit.

The panel is reviewing seven compounds, including TB-500, BPC-157, MOTs-C and Semax, none of which has completed the large-scale human trials normally required for FDA drug approval. FDA career scientists have recommended against allowing compounding pharmacies to produce any of the seven, citing insufficient clinical evidence and risks such as cancer promotion or adverse immune responses, while critics such as UC Davis's Paul Knoepfler stress they remain scientifically unproven. Health Secretary Robert F. Kennedy Jr. has publicly backed easing the restrictions, and the FDA has recently restructured the advisory committee to include members with industry ties, adding a political dimension to the debate.